Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study on the Treatment of Refractory Immune-related Cytopenia With CD20 Monoclonal Antibody Combined With BTK Inhibitor (BTKi)

NCT07574073 is registered in ClinicalTrials.gov with Qi deng as lead sponsor.

NCT NCT07574073
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07574073 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study on the Treatment of Refractory Immune-related Cytopenia With CD20 Monoclonal Antibody Combined With BTK Inhibitor (BTKi)
Lead sponsor
Qi deng
Phase
Phase 1
Overall status
Not yet recruiting
Start date
June 1, 2026
Completion date
May 31, 2028
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

anti-cd20 monoclonal antibody, autoimmune hemolytic anemia (aiha), btk inhibitors, immune thrombocytopenia (itp)